<!doctype html><html><head><meta charset=utf-8><title>COVID-19 vaccines adverse events: myocarditis, pericarditis, etc. (99 million people, not US)</title>
<link rel=stylesheet href="/css/main.css?v=1748384341"><link rel=stylesheet href="/css/pagination.css?v=1748384341"><link rel=stylesheet href=https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.4.0/css/all.min.css><script src=https://unpkg.com/lunr/lunr.js></script><script src=https://cdn.jsdelivr.net/npm/pako@2.1.0/dist/pako.min.js></script><script src="/js/search.js?v=1748384341"></script></head><body><div class=top-nav><div class=home-icon><a href=/ title="Go to Home Page"><svg viewBox="0 0 576 512" width="28" height="28"><path d="M575.8 255.5c0 18-15 32.1-32 32.1h-32l.7 160.2c0 2.7-.2 5.4-.5 8.1V472c0 22.1-17.9 40-40 40H456c-1.1.0-2.2.0-3.3-.1-1.4.1-2.8.1-4.2.1H416 392c-22.1.0-40-17.9-40-40V448 384c0-17.7-14.3-32-32-32H256c-17.7.0-32 14.3-32 32v64 24c0 22.1-17.9 40-40 40H160 128.1c-1.5.0-3-.1-4.5-.2-1.2.1-2.4.2-3.6.2H104c-22.1.0-40-17.9-40-40V360c0-.9.0-1.9.1-2.8V287.6H32c-18 0-32-14-32-32.1.0-9 3-17 10-24L266.4 8c7-7 15-8 22-8s15 2 21 7L564.8 231.5c8 7 12 15 11 24z"/></svg></a></div><div class=search-container><div class=search-icon><i class="fas fa-search"></i></div><input type=text id=search-input placeholder=Search... disabled><div id=suggestions class=search-suggestions style=display:none></div><ul id=search-results style=display:none></ul><div id=search-results-panel class=search-results-panel><div class=results-header>Search Results</div><ul id=search-results-panel-list class=results-list></ul></div></div></div><div class=container><div class="content content-full-width" role=main><article><h1>COVID-19 vaccines adverse events: myocarditis, pericarditis, etc. (99 million people, not US)</h1><time>March 13, 2024</time><nav id=TableOfContents><ul><li><ul><li><ul><li><a href=#covid-19-vaccines-and-adverse-events-of-special-interest-a-multinational-global-vaccine-data-network-gvdn-cohort-study-of-99-million-vaccinated-individuals>COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals</a></li><li><a href=#vitamindwiki-273-a-hrefpostsvaccination-pages-in-vitamindwiki-stylecolor-red-text-decoration-underline-titlethis-postcategory-does-not-exist-yet-vaccination-pages-in-vitamindwikivaccination-pages-in-vitamindwikia>VitaminDWiki: 273+ <a href=/posts/vaccination-pages-in-vitamindwiki style=color:red;text-decoration:underline title="This post/category does not exist yet: Vaccination pages in VitaminDWiki">Vaccination pages in VitaminDWiki</a></a></li></ul></li></ul></li></ul></nav><hr><h4 id=covid-19-vaccines-and-adverse-events-of-special-interest-a-multinational-global-vaccine-data-network-gvdn-cohort-study-of-99-million-vaccinated-individuals>COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals</h4><p>Vaccine <a href=https://doi.org/10.1016/j.vaccine.2024.01.100>https://doi.org/10.1016/j.vaccine.2024.01.100</a></p><p>K. Faksova a, D. Walsh b c, Y. Jiang b c, J. Griffin c, A. Phillips d, A. Gentile e, J.C. Kwong f g h, K. Macartney d i, M. Naus j n, Z. Grange k, S. Escolano l, G. Sepulveda m, A. Shetty m, A. Pillsbury d, C. Sullivan k, Z. Naveed j n, N.Z. Janjua j n, N. Giglio e, J. Perälä o, S. Nasreen f p x…A. Hviid a w</p><p><strong>This summary is NOT in the PDF</strong></p><img src=https://d1bk1kqxc0sym.cloudfront.net/attachments/png/vaccine-problems-clipped.png alt=image width=300><p>Major color groups used for different pharmas:</p><p>    <span style=color:#f06>Red = Moderna</span>, <span style=color:#00f>Blue = Pfizer,</span> <span style=color:#f96>Amber = AstraZeneca</span></p><p>Shades within the groups related to different doses of the particular pharma&rsquo;s &ldquo;vaccine&rdquo;</p><img src=https://d1bk1kqxc0sym.cloudfront.net/attachments/png/42-days.png alt=image width=350><p>Background</p><p>The Global COVID Vaccine Safety (GCoVS) Project, established in 2021 under the multinational Global Vaccine Data Network™ (GVDN®), facilitates comprehensive assessment of vaccine safety. This study aimed to evaluate the risk of adverse events of special interest (AESI) following COVID-19 vaccination from 10 sites across eight countries.</p><p>Methods</p><p>Using a common protocol, this observational cohort study compared observed with expected rates of 13 selected AESI across neurological, haematological, and cardiac outcomes. Expected rates were obtained by participating sites using pre-COVID-19 vaccination healthcare data stratified by age and sex. Observed rates were reported from the same healthcare datasets since COVID-19 vaccination program rollout. AESI occurring up to 42 days following vaccination with mRNA (BNT162b2 and mRNA-1273) and adenovirus-vector (ChAdOx1) vaccines were included in the primary analysis. Risks were assessed using observed versus expected (OE) ratios with 95 % confidence intervals. Prioritised potential safety signals were those with <strong>lower bound of the 95 % confidence interval (LBCI) greater than 1.5.</strong></p><p>Results</p><p>Participants included 99,068,901 vaccinated individuals. In total, 183,559,462 doses of BNT162b2, 36,178,442 doses of mRNA-1273, and 23,093,399 doses of ChAdOx1 were administered across participating sites in the study period. Risk periods following homologous vaccination schedules contributed 23,168,335 person-years of follow-up. OE ratios with LBCI > 1.5 were observed for Guillain-Barré syndrome (2.49, 95 % CI: 2.15, 2.87) and cerebral venous sinus thrombosis (3.23, 95 % CI: 2.51, 4.09) following the first dose of ChAdOx1 vaccine. Acute disseminated encephalomyelitis showed an OE ratio of 3.78 (95 % CI: 1.52, 7.78) following the first dose of mRNA-1273 vaccine. The OE ratios for myocarditis and pericarditis following BNT162b2, mRNA-1273, and ChAdOx1 were significantly increased with LBCIs > 1.5.</p><p>Conclusion</p><p>This multi-country analysis confirmed pre-established safety signals for myocarditis, pericarditis, Guillain-Barré syndrome, and cerebral venous sinus thrombosis. Other potential safety signals that require further investigation were identified.</p><p><strong><i class="fas fa-file-pdf" style=margin-right:.3em></i><a href=https://d1bk1kqxc0sym.cloudfront.net/attachments/pdf/multinational-global-vaccine-data-network-compresspdf.pdf>Download the PDF from VitaminDWiki</a></strong></p><p>URL = <a href=https://www.globalvaccinedatanetwork.org/>https://www.globalvaccinedatanetwork.org/</a></p><p><strong>Full summary chart</strong></p><img src=https://d1bk1kqxc0sym.cloudfront.net/attachments/png/vaccine-problems.png alt=image width=600><hr><h5 id=dr-talked-with-authors-then-made-video-study-did-not-look-at-long-covid-problems>Dr. talked with authors then made video: study did not look at long-COVID problems</h5><p><strong><a href="https://www.youtube.com/watch?v=K0Abk5q_z_c&amp;t=22s&amp;ab_channel=DrbeenMedicalLectures">Drbeen</a> 39 minutes</strong></p><hr><h4 id=vitamindwiki-273-a-hrefpostsvaccination-pages-in-vitamindwiki-stylecolor-red-text-decoration-underline-titlethis-postcategory-does-not-exist-yet-vaccination-pages-in-vitamindwikivaccination-pages-in-vitamindwikia>VitaminDWiki: 273+ <a href=/posts/vaccination-pages-in-vitamindwiki style=color:red;text-decoration:underline title="This post/category does not exist yet: Vaccination pages in VitaminDWiki">Vaccination pages in VitaminDWiki</a></h4></article></div></div><script src="/js/lightspa.js?v=1748384341"></script><script>const spa=new LightSPA({mainContentSelector:'[role="main"]',navigationSelector:"[data-spa-nav]"});window.search=new Search({documentsUrl:"/search/search_documents.json.gz?v=1748384341",indexUrl:"/search/search_index.json.gz?v=1748384341"}),document.addEventListener("DOMContentLoaded",function(){function e(e){var t=e.querySelector(".category-expander"),n=e.querySelector(".subcategory-list");e.classList.contains("collapsed")?(e.classList.remove("collapsed"),e.classList.add("expanded"),t.textContent="-",n.style.display="block"):(e.classList.remove("expanded"),e.classList.add("collapsed"),t.textContent="+",n.style.display="none")}document.querySelectorAll(".category-expander").forEach(function(t){t.addEventListener("click",function(t){t.stopPropagation();var n=this.closest(".top-level-category");e(n)})}),document.querySelectorAll(".category-name").forEach(function(t){t.addEventListener("click",function(t){t.stopPropagation();var n=this.closest(".top-level-category");e(n)})})})</script><script src="/js/toc-sanitizer.js?v=1748384341"></script><script src="/js/search-results-panel.js?v=1748384341"></script><script src="/js/tiki-redirects.js?v=1748384341"></script></body></html>